Accel Entertainment (NYSE:ACEL) Posts Better

Accel Entertainment (NYSE:ACEL) reported Q2 CY2026 results. Revenue rose 9.6% year on year to $368.1 million and exceeded Wall Street estimates by 3.3%, according to the article. GAAP EPS was $0.15, up from $0.08, but below analysts’ consensus. Operating margin was 8.7%. Full-year EPS is expected to rise to $0.75 from $0.67.

Original reporting
Published Aug 4, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Accel Entertainment (NYSE:ACEL) Posts Better — source image
Decision brief

The 30-second read

$ACELNeutralMed
01

Why it matters

The quarter shows revenue outperformance and stable profitability, but the EPS miss and a lower expected revenue growth rate over the next 12 months introduce near-term caution.

02

Market read

Traders can reassess near-term earnings power and growth trajectory after the Q2 print, especially given the deceleration in expected revenue growth.

03

What to watch

The article highlights stable operating margin and terminal sales growth (29,281, +6.2% YoY average over two years), which could support a re-rating if subsequent quarters sustain monetization despite slower topline growth.

Relevance 7/10Novelty 6/10Timing: after-hours/late-day earnings reaction context, stock noted flat at $12.17 immediately after reporting

Background

Accel Entertainment is an electronic gaming machines and interactive amusement terminals operator, reporting Q2 CY2026 results versus Wall Street expectations.

Company-level read

Ticker impact

$ACELNeutralMedium confidence
Context

Accel Entertainment reported Q2 CY2026 revenue of $368.1M, up 9.6% YoY, beating estimates by 3.3%, while EPS missed at $0.15.

Expected impact

Near-term bias neutral to slightly negative if investors focus on EPS miss and decelerating revenue outlook.

Evidence & confidence

The article provides a concrete earnings datapoint (revenue beat, EPS miss) plus a forward revenue growth expectation of 3.3% over 12 months, which can offset the revenue upside despite stable operating margin (8.7%).

Market effects

Signals mixed demand momentum for electronic gaming terminal operators, with monetization improving but growth decelerating.

No specific regional demand or regulatory changes cited.

No global expansion or international regulatory developments mentioned.

Counterpoint

Investors may look past the EPS miss if EBITDA outperformed and monetization improved via higher revenue per terminal, treating the quarter as quality rather than weakness.

Key entities

  • Accel Entertainment

    Reported Q2 CY2026 revenue beat, EPS miss, stable operating margin, and provided forward-looking sell-side revenue growth expectations.

Related articles

$ACELMed

Accel Entertainment, Inc. (ACEL): Results of Operations and Financial Condition

Accel Entertainment, Inc. (ACEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document Accel Entertainment Reports Quarterly Record Revenue of $368 Million in the Second Quarter of 2026 Net Income rose 72% year-over-year Chicago, IL – August 4, 2026 – Accel Entertainment, Inc. (NYSE: ACEL), a leading locals-

$PBRMedAI 8/10

Petrobras Q2 Profit Nearly Doubles as Oil Production Hits Record

Petrobras reported Q2 2026 net income of R$52.4 billion ($10.4 billion), up 97% year over year, with adjusted EBITDA of R$93.8 billion. Operating cash flow rose 46% to R$61.8 billion. Record upstream output and higher crude prices supported results. The board approved R$17.4 billion in dividends and interest on equity; gross debt was $70.8 billion.

$RMDMed

CPAP machine maker posts record revenue but shares sink

ResMed, an ASX-listed CPAP maker, reported record Q4 revenue of US$1.5B and FY2025/26 revenue of US$5.7B, up 10%. Full-year net income rose 9% to US$1.5B, but gross margin was 62.3% versus 62.7% expected, which the company attributed to inflation. ResMed plans modest 2026/27 price increases. Shares fell 4.9% to $29.94.